Asymbio Shanghai Fengxian Base Commences Commercial-Scale Production
Asymbio Successfully Passed the EU QP Audit
AsymBio's Center of Biological Technology and Innovation was established
Commercial production facilities for antibodies and bioconjugates were launched
Plasmid and mRNA pilot plant in Suzhou was launched
The capability for laboratory R&D projects for plasmids and mRNAs was established
The capability for laboratory development of bioconjugates was established
The capability for early-stage development and production of antibodies wasestablished
AsymBio was founded
Pharmaceutical Service Provider of the Year (CXO), 3rd Biopharmaceutical Industry Ranking
TOP 10 CGT CDMO with the Most Potential, CGCS 2023
CDMO of the Year, CGT Industry Stars 2023
Future Top 100 CDMOs in Medical Care
Top 10 CGT CDMO with the Most Potential, China Pharmaceutical Industry List
Best ADC Platform Technology，the 12th World ADC Awards
